Archiv.zip (660.42 kB)

Archiv.zip

This item is shared privately

dataset

modified on 2017-03-30, 19:47

This file consists of the data set used to reach the conclusions drawn in the manuscript "Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis". The applied methods can be found in the manuscript. The study was approved by the ethics committee of the Hamburg Chamber of Physicians (PV3983 10.4.2012 and PV3955 5.1.2012).

Keywords

natalizumab multiple sclerosis therapy management therapy adherence therapy discontinuation progressive multifocal leukoencephalopathy therapeutic risk risk acceptance risk perception Neurology and Neuromuscular Diseases

Licence

CC BY 4.0

Archiv.zip

Categories

Keywords

Licence